Phase 4
Completed N=16
24-hour IOP-lowering Effect of 0.01% Bimatoprost
Intraocular Pressure · Glaucoma · Hypertension
Source: ClinicalTrials.gov NCT01271686 ↗
Enrolled (actual)
16
Serious AEs
0.0%
Results posted
Jun 2014
Primary outcomePrimary: Nocturnal Intraocular Pressure (IOP) Change — -2.6 mmHg
Summary
This study will evaluate the 24-hour IOP-lowering efficacy of 0.01% bimatoprost once daily in patients with glaucoma or ocular hypertension
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Nocturnal Intraocular Pressure (IOP) Change |
-2.6 | — |
Eligibility Criteria
Inclusion Criteria
- primary open-angle glaucoma or ocular hypertension
Exclusion Criteria
- Women of childbearing potential previous glaucoma surgery presence of other eye disease
Data sourced from ClinicalTrials.gov (NCT01271686). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.